Show simple item record

dc.contributor.authorBallester-Clau, Raquel
dc.contributor.authorTorres Vicente, Gisela
dc.contributor.authorVoltà-Pardo, Tania
dc.contributor.authorLópez-Barroso, Laura
dc.contributor.authorCucala-Ramos, Mercedes
dc.contributor.authorReñé Espinet, Josep Maria
dc.contributor.authorPlanella de Rubinat, Montse
dc.description.abstractObjective The aim of this study was to assess the efficacy and safety of intravenous ferric carboxymaltose (FCM) following hospitalization for acute gastrointestinal bleeding (AGIB) in the context of a restrictive transfusion strategy. Patients and methods A retrospective single-center study analyzed patients with AGIB (excluding AGIB secondary to portal hypertension) administered a single FCM dose with or without blood transfusion. Results Eighty-six episodes in 84 patients were analyzed. Seventy-nine patients had upper AGIB. Nineteen episodes were associated with hemodynamic instability. FCM was administered during hospitalization as a single dose of 1000mg iron in 84/86 episodes and as a single dose of 500mg iron in two episodes, with blood transfusion in 60/86 (69.8%) episodes. The mean hemoglobin (Hb) was 9.0g/dl at admission, 7.6g/dl at the lowest in-hospital value, 9.4g/dl at discharge, and 12.7g/dl at followup (mean: 55 days postdischarge) (P<0.001 for follow-up vs. all other timepoints). The lowest mean in-hospital Hb value was 7.2 and 8.8g/dl, respectively, in patients with transfusion+FCM versus FCMalone; the mean Hb was 12.4 versus 13.7g/dl at followup. In patients administered FCM alone, the mean Hb at follow-up in the subpopulations aged older than or equal to 75 years (n=33), Charlson comorbidity index of at least 3 (n=48), and Hb of up to 10g/dl at admission (n=47) were 12.6, 13.1, and 13.3g/dl, respectively. No adverse effects were detected. Conclusion Treatment with FCM for AGIB is associated with a good erythropoietic response and anemia correction after hospitalization, even in severe episodes or when transfusion is needed. FCM is safe and well tolerated, and may support a restrictive transfusion policy. Eur J Gastroenterol Hepatol 31:116–122ca_ES
dc.description.sponsorshipData analysis and medical writing support from a freelance medical writer (C. Dunstall) were funded by Vifor Pharma, Glattbrugg, Switzerland.ca_ES
dc.publisherLippincott, Williams & Wilkinsca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofEuropean Journal of Gastroenterology and Hepatology, 2019, vol. 31, núm. 1, p. 116-122ca_ES
dc.rightscc-by-nc-nd (c) Raquel Ballester et al., 2019ca_ES
dc.titleClinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleedingca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by-nc-nd (c) Raquel Ballester et al., 2019
Except where otherwise noted, this item's license is described as cc-by-nc-nd (c) Raquel Ballester et al., 2019